Conclusions: This study shows real-world Romanian efficacy and over the time response of administering the new classes in T2DM patients when aiming for HbA1c < 7% levels and 5% BWR, with SGLT-2i outperforming metformin and GLP-1 RAs, emphasizing their growing role in the management of T2DM. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.